Uncategorized
LUMINOUS study interim results show VA preserved with ranibizumab
CHICAGO — One- and 2-year follow-up data indicate expected preservation of visual acuity with relatively few injections of ranibizumab in patients with neovascular age-related macular degeneration, a speaker here said.Giving results from the second interim analysis of the LUMINOUS study, Paul Mitchell, MD, PhD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting that patients in the study represented a more diverse demographic population than patients in other pivotal trials of Lucentis (ranibizumab, Genentech) and, therefore, are more representative of real-world patients.